Novo’s Wegovy, Ozempic List Price Cuts Reflect Competitive Pressures, Policy Environment
The move is aligned with a growing industry shift toward lowering list prices to current net pricing levels and eliminating rebates.
Scrip - February 24, 2026

Bayer Sues J&J Over Claims From RWE Study Of Erleada Vs. Nubeqa
The German drugmaker alleges false advertising by J&J and methodological flaws in its real-world evidence analysis, which it presented at a conference earlier this month.
Scrip - February 24, 2026

Biopharma Dealmaking Bounced Back In A Big Way In 2025
INFOGRAPHIC: After M&A and alliance metrics plunged across the board in 2024, 2025 produced significantly higher total and average values in both categories.
Scrip - February 24, 2026

QurAlis In Fundraising Mode After Potentially Value-Creating Readout In ALS
The company’s next VC round hinged on Phase I results for QRL-201, an antisense oligonucleotide designed to restore STMN2 expression in ALS patients, and topline data are promising.
Scrip - February 24, 2026

Abcuro Fails Phase II/III Myositis Study But Wants To Continue
Although ulviprubart missed the primary and key secondary endpoints in inclusion body myositis, the company claims the drug might have potential in mild-to-moderate disease.
Scrip - February 24, 2026

BioMarin Leans Into BD As Voxzogo Competition Intensifies
After announcing the acquisitions of Inozyme and Amicus last year, the rare disease specialist is continuing to scout out pipeline expansion opportunities.
Scrip - February 24, 2026

Novo And United’s Triple G Agonist Outpaces Lilly Rival On Weight Loss
UBT251 produced weight loss of nearly 20% in less than six months in a Phase II China study, making it competitive with Lilly’s retatrutide.
Scrip - February 24, 2026

Stock Watch: Vaccine Rivals Catch Market Chill
Despite disease outbreaks highlighting the importance of prevention, antivax sentiment and political headwinds have brought significant challenges to the vaccine industry, while competitive dynamics are adding pricing pressure.
Scrip - February 24, 2026

New Biotech Slate Medicines Launched With Anti-PACAP Antibody For Migraine
Emerging from stealth mode, Slate has revealed an in licensed anti PACAP migraine program, entering a field that includes efforts from Lundbeck.
Scrip - February 24, 2026

Biokin’s Iza-Bren Scores Second Phase III OS Win In China Trial
Sichuan Biokin Pharmaceutical’s iza-bren hit the co-primary endpoints of OS and PFS in a Phase III clinical study in Chinese patients with triple-negative breast cancer in the second and later-line settings.
Scrip - February 24, 2026

Astellas Bolsters Prostate Cancer Pipeline With Global VIR-5500 Deal
Vir enters major global deal worth up to $1.7bn for T-cell engager VIR-5500 in an alliance that will also expand partner Astellas's immuno-oncology pipeline ahead of a major expiry.
Scrip - February 24, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Hudson’s legacy at Sanofi; the realities behind Trump’s US pharma investment push; Bayer’s precision medicine approach and growth; clinical trials to look out for this year; and Scrip Asks on AI and operational excellence.
Scrip - February 24, 2026

Allurion Obesity Treatment Device Wins FDA Approval
The system, which can be swallowed in a physician’s office and does not require surgery, has been cleared for use in adults aged 22-65 who have failed in at least one weight loss program.
Medtech Insight - February 24, 2026

Reimbursement Still Missing Piece As Neuroscience Speeds Ahead
Device-based neurotherapeutics face a coverage gap that drug developers do not, and as the field moves toward combination approaches, that asymmetry could undermine important innovation.
Medtech Insight - February 24, 2026

Oura To Test Custom Large Language Model For Women’s Health
Oura is testing a women’s health–focused LLM within its app, aiming to deliver personalized, educational guidance across life stages.
Medtech Insight - February 24, 2026

PrettyBoy Skin Care Referred To FTC For Failure To Comply With NAD
The National Advertising Division refers men’s skin care marketer, PrettyBoy, Inc. to the FTC for possible enforcement action after the Milwaukee firm says it will not comply with a recommendation to discontinue before-and-after photos in Internet ads.
HBW Insight - February 25, 2026

The State Of The Union: AAM’s Murphy Sets Out Achievements And Obstacles In US
AAM president and CEO John Murphy summarized a year of progress for the off-patent industry in front of an audience of generics and biosimilars industry delegates at the AAM’s Access! 2026 annual conference – but also said more efforts were needed to create a sustainable future environment.
Generics Bulletin - February 24, 2026

Sandoz Eyes H2 2026 Launch For Lupin-Partnered EU Ranibizumab
Sandoz will look to muscle in on a crowded biosimilar ophthalmology market with the launch of a rival to Lucentis later this year.
Generics Bulletin - February 24, 2026

Teva’s US Korlym Infringement Victory Is Upheld On Appeal
Corcept said it would “vigorously defend our rights” and is “currently considering the best way to pursue judicial review of this decision.”
Generics Bulletin - February 24, 2026

Neuroscience’s Reimbursement Problem
Device-based neurotherapeutics face a coverage gap that drug developers do not, and as the field moves toward combination approaches, that asymmetry could undermine important innovation.
In Vivo - February 23, 2026

Pressure, Pivot And The Promise Of AI: BCG Maps Biopharma’s Defining Challenges For 2026
Recent BCG reports and interviews reveal an industry under pressure and racing to adapt through AI, new deal structures and direct-to-patient models.
In Vivo - February 23, 2026

20 Voices: What Does 2026 Hold For Biopharma?
Twenty biopharma leaders share predictions for 2026 – from shifting dealmaking dynamics and Asia's rise as an innovation epicenter to new frontiers in oncology, obesity and cell therapy, and AI's operational reckoning.
In Vivo - February 23, 2026

Big Promises, Long Timelines – Trump’s US Pharma Investment Push
While investment promises appear to be in billions of dollars, industry experts remain skeptical.
In Vivo - February 23, 2026